American Vanguard (AVD) 10-Q 7 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Jul. 30, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	0000005981
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		30,199,867
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-13795
Entity Tax Identification Number	952588080
Entity Address, Address Line One	4695 MacArthur Court
Entity Address, City or Town	Newport Beach
Entity Address, State or Province	California
Entity Address, Postal Zip Code	92660
City Area Code	949
Local Phone Number	260-1200

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Net sales	$ 113,104	$ 107,046	$ 212,780	$ 211,154
Cost of sales	71,451	63,749	129,425	126,806
Gross profit	41,653	43,297	83,355	84,348
Operating expenses	35,362	34,718	70,162	68,418
Operating income	6,291	8,579	13,193	15,930
Interest expense, net	1,925	966	3,537	1,803
Income before provision for income taxes and loss on equity method investments	4,366	7,613	9,656	14,127
Income tax expense	1,224	1,748	2,584	3,440
Income before loss on equity method investments	3,142	5,865	7,072	10,687
Loss from equity method investments	36	301	60	518
Net income	3,106	5,564	7,012	10,169
Net income attributable to non-controlling interest		35		85
Net income attributable to American Vanguard	$ 3,106	$ 5,599	$ 7,012	$ 10,254
Earnings per common share—basic	$ 0.11	$ 0.19	$ 0.24	$ 0.35
Earnings per common share—assuming dilution	$ 0.11	$ 0.19	$ 0.24	$ 0.34
Weighted average shares outstanding—basic	29,001	29,330	28,989	29,309
Weighted average shares outstanding—assuming dilution	29,540	30,190	29,560	30,113

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 3,106	$ 5,564	$ 7,012	$ 10,169
Comprehensive income:
Foreign currency translation adjustment	657	(898)	(1,112)	(226)
Comprehensive income	3,763	4,666	5,900	9,943
Net income attributable to non-controlling interest		35		85
Comprehensive income attributable to American Vanguard	$ 3,763	$ 4,701	$ 5,900	$ 10,028

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 6,307	$ 6,168
Receivables:
Trade, net of allowance for doubtful accounts of $1,707 and $1,263, respectively	118,351	123,320
Other	12,679	10,709
Total receivables, net	131,030	134,029
Inventories, net	193,393	159,895
Prepaid expenses	11,717	10,096
Income taxes receivable	445
Total current assets	342,892	310,188
Property, plant and equipment, net	53,637	49,252
Operating lease right-of-use assets	12,420
Intangible assets, net of amortization	194,337	186,583
Goodwill	39,436	25,790
Other assets	23,087	21,774
Total assets	665,809	593,587
Current liabilities:
Current installments of other liabilities	1,320	1,609
Accounts payable	62,220	66,535
Deferred revenue	751	20,043
Accrued program costs	49,172	37,349
Accrued expenses and other payables	11,085	15,962
Operating lease liabilities, current	4,749
Income taxes payable		4,030
Total current liabilities	129,297	145,528
Long-term debt, net of deferred loan fees	164,574	96,671
Operating lease liabilities, long-term	7,744
Other liabilities, excluding current installments	10,982	6,795
Deferred income tax liabilities	19,364	15,363
Total liabilities	331,961	264,357
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 33,204,191 shares at June 30, 2019 and 32,752,827 shares at December 31, 2018	3,321	3,276
Additional paid-in capital	85,614	83,177
Accumulated other comprehensive loss	(5,619)	(4,507)
Retained earnings	268,692	262,840
Total stockholders' equity including treasury stock	352,008	344,786
Less treasury stock at cost, 3,061,040 shares at June 30, 2019 and 2,902,992 shares at December 31, 2018	(18,160)	(15,556)
Total stockholders’ equity	333,848	329,230
Total liabilities and stockholders' equity	$ 665,809	$ 593,587

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 1,707	$ 1,263
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	33,204,191	32,752,827
Treasury stock, shares	3,061,040	2,902,992

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Retained Earnings	Treasury Stock	AVD Total	Non- Controlling Interest
Balance at Dec. 31, 2017	$ 305,314	$ 3,225	$ 75,658	$ (4,507)	$ 238,953	$ (8,269)	$ 305,060	$ 254
Balance (in shares) at Dec. 31, 2017		32,241,866				2,450,634
Adjustment to recognize new revenue recognition standard, net of tax	2,214				2,214		2,214
Adjustment to recognize new standard on taxeson foreign asset transfers	(180)				(180)		(180)
Common stock issued under ESPP	299	$ 1	298				299
Common stock issued under ESPP, (in Shares)		17,078
Cash dividends on common stock ($0.02 per share)	(586)				(586)		(586)
Foreign currency translation adjustment, net	672			672			672
Stock based compensation	1,309		1,309				1,309
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes)	511	$ 41	470				511
Stock options exercised; grants, termination, and vesting of restricted stock units (net of shares in lieu of taxes), Shares		409,979
Net income	4,605				4,655		4,655	(50)
Balance at Mar. 31, 2018	314,158	$ 3,267	77,735	(3,835)	245,056	$ (8,269)	313,954	204
Balance (in shares) at Mar. 31, 2018		32,668,923				2,450,634
Balance at Dec. 31, 2017	305,314	$ 3,225	75,658	(4,507)	238,953	$ (8,269)	305,060	254
Balance (in shares) at Dec. 31, 2017		32,241,866				2,450,634
Foreign currency translation adjustment, net	(226)
Net income	10,169
Balance at Jun. 30, 2018	320,231	$ 3,275	79,721	(4,733)	250,068	$ (8,269)	320,062	169
Balance (in shares) at Jun. 30, 2018		32,743,504				2,450,634
Balance at Mar. 31, 2018	314,158	$ 3,267	77,735	(3,835)	245,056	$ (8,269)	313,954	204
Balance (in shares) at Mar. 31, 2018		32,668,923				2,450,634
Cash dividends on common stock ($0.02 per share)	(587)				(587)		(587)
Foreign currency translation adjustment, net	(898)			(898)			(898)
Stock based compensation	1,469		1,469				1,469
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes)	525	$ 8	517				525
Stock options exercised; grants, termination, and vesting of restricted stock units (net of shares in lieu of taxes), Shares		74,581
Net income	5,564				5,599		5,599	(35)
Balance at Jun. 30, 2018	320,231	$ 3,275	79,721	(4,733)	250,068	$ (8,269)	320,062	$ 169
Balance (in shares) at Jun. 30, 2018		32,743,504				2,450,634
Balance at Dec. 31, 2018	$ 329,230	$ 3,276	83,177	(4,507)	262,840	$ (15,556)	329,230
Balance (in shares) at Dec. 31, 2018	32,752,827	32,752,827				2,902,992
Common stock issued under ESPP	$ 338	$ 2	336				338
Common stock issued under ESPP, (in Shares)		22,441
Cash dividends on common stock ($0.02 per share)	(580)				(580)		(580)
Foreign currency translation adjustment, net	(1,769)			(1,769)			(1,769)
Stock based compensation	1,485		1,485				1,485
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes)	(888)	$ 42	(930)				(888)
Stock options exercised; grants, termination, and vesting of restricted stock units (net of shares in lieu of taxes), Shares		419,295
Shares repurchased	(2,604)					$ (2,604)	(2,604)
Shares repurchased (In Shares)						158,048
Net income	3,906				3,906		3,906
Balance at Mar. 31, 2019	329,118	$ 3,320	84,068	(6,276)	266,166	$ (18,160)	329,118
Balance (in shares) at Mar. 31, 2019		33,194,563				3,061,040
Balance at Dec. 31, 2018	$ 329,230	$ 3,276	83,177	(4,507)	262,840	$ (15,556)	329,230
Balance (in shares) at Dec. 31, 2018	32,752,827	32,752,827				2,902,992
Foreign currency translation adjustment, net	$ (1,112)
Net income	7,012
Balance at Jun. 30, 2019	$ 333,848	$ 3,321	85,614	(5,619)	268,692	$ (18,160)	333,848
Balance (in shares) at Jun. 30, 2019	33,204,191	33,204,191				3,061,040
Balance at Mar. 31, 2019	$ 329,118	$ 3,320	84,068	(6,276)	266,166	$ (18,160)	329,118
Balance (in shares) at Mar. 31, 2019		33,194,563				3,061,040
Cash dividends on common stock ($0.02 per share)	(580)				(580)		(580)
Foreign currency translation adjustment, net	657			657			657
Stock based compensation	1,510		1,510				1,510
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes)	37	$ 1	36				37
Stock options exercised; grants, termination, and vesting of restricted stock units (net of shares in lieu of taxes), Shares		9,628
Net income	3,106				3,106		3,106
Balance at Jun. 30, 2019	$ 333,848	$ 3,321	$ 85,614	$ (5,619)	$ 268,692	$ (18,160)	$ 333,848
Balance (in shares) at Jun. 30, 2019	33,204,191	33,204,191				3,061,040

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018
Statement Of Stockholders Equity [Abstract]
Cash dividends on common stock, per share	$ 0.02	$ 0.02	$ 0.02	$ 0.02

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net income	$ 7,012	$ 10,169
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of property, plant and equipment and intangible assets	9,233	9,516
Amortization of other long term assets	2,146	2,313
Amortization of discounted liabilities		202
Provision for bad debts	445	181
Revision of deferred compensation	(2,888)	(1,468)
Stock-based compensation	2,995	2,778
Change in deferred income taxes	(572)	(26)
Loss from equity method investments	60	518
Changes in assets and liabilities associated with operations:
Decrease in net receivables	7,841	5,297
Increase in inventories	(27,635)	(40,194)
Increase in prepaid expenses and other assets	(1,844)	(707)
Increase in net operating lease liability	73
Increase in income tax receivable/payable, net	(4,480)	(271)
(Decrease) increase in accounts payable	(10,138)	11,309
Decrease in deferred revenue	(19,438)	(7,254)
Increase in accrued program costs	11,823	15,039
Decrease in other payables and accrued expenses	(6,719)	(3,683)
Net cash (used in) provided by operating activities	(32,086)	3,719
Cash flows from investing activities:
Capital expenditures	(7,216)	(3,230)
Acquisition of business, product lines, and intangible assets	(24,302)	(1,631)
Net cash used in investing activities	(31,518)	(4,861)
Cash flows from financing activities:
Payments under line of credit agreement	(54,200)	(62,125)
Borrowings under line of credit agreement	122,000	58,800
Net (payments) receipts from the issuance of common stock (sale of stock under ESPP, exercise of stock options, and shares purchased for tax withholding)	(513)	1,335
Repurchase of common stock	(2,604)
Payment of cash dividends	(1,160)	(1,024)
Net cash provided by (used in) financing activities	63,523	(3,014)
Net decrease in cash and cash equivalents	(81)	(4,156)
Effect of exchange rate changes on cash and cash equivalents	220	(82)
Cash and cash equivalents at beginning of period	6,168	11,337
Cash and cash equivalents at end of period	$ 6,307	$ 7,099

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Leases

Leases	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases	2. Leases— The Company has operating leases for warehouses, manufacturing facilities, offices, cars, railcars and certain equipment. On January 1, 2019, the Company adopted the accounting and adoption guidance in Accounting Standards Codification (“ASC”) 842, Leases, for its operating leases resulting in the recognition of operating lease right-of-use (ROU) assets and lease liabilities on the effective date. The Company measures ROU assets throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. The lease liabilities are measured at the present value of the unpaid lease payments at the lease commencement date. Leases that include both lease and non-lease components are accounted for as a single lease component for each asset class. The minimum payments under operating leases are recognized on a straight-line basis over the lease term in the condensed consolidated statements of operations. Operating lease expenses related to variable lease payments are recognized in cost of sales or as operating expenses in a manner consistent with the nature of the underlying lease and as the events, activities, or circumstances in the lease agreement occur. Leases with a term of less than 12 months are not recognized on the condensed consolidated balance sheets, and the related lease expenses are recognized in the condensed consolidated statements of operations on a straight-line basis over the lease term. The accounting for leases requires management to exercise judgment and make estimates in determining the applicable discount rate, lease term and payments due under a lease. Most of our leases do not provide an implicit interest rate, nor is it available to us from our lessors. As an alternative, we use our estimated incremental borrowing rate, which is derived from information available at the lease commencement date, including publicly available data, in determining the present value of lease payments. We also estimated the fair value of the lease and non-lease components for some of our warehouse leases based on market data and cost data. The lease term includes the non-cancellable period of the lease plus any additional periods covered by either an option to extend (or not terminate) that the Company is reasonably certain to exercise. The Company has leases with a lease term ranging from 1 year to 15 years. The operating leases of the Company do not contain major restrictions or covenants such as those relating to dividends or additional financial obligations. Finance leases are immaterial to the condensed consolidated financial statements. There were no lease transactions with related parties as of June 30, 2019. The operating lease expense for the three and six months ended June 30, 2019 was $1,400 and $2,758, respectively. Lease expenses related to variable lease payments and short term leases were immaterial. Additional information related to operating leases are as follows: Three months ended March 31, 2019 Six months ended June 30, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 1,348 $ 2,685 ROU assets obtained in exchange for new liabilities $ 1,682 $ 2,052 The weighted-average remaining lease term and discount rate related to the operating leases as of June 30, 2019 were as follows: Weighted-average remaining lease term (in years) 3.44 Weighted-average discount rate 3.71 % Future minimum lease payments under non-cancellable operating leases as of June 30, 2019 were as follows: June 30, 2019 Remainder of 2019 $ 2,611 2020 4,792 2021 2,834 2022 1,299 2023 688 Thereafter 1,183 Total lease payments $ 13,407 Less: imputed interest 914 Total $ 12,493 Amounts recognized in the condensed consolidated balance sheet: Operating lease liabilities, current $ 4,749 Operating lease liabilities, long term $ 7,744

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2019
Revenue From Contract With Customer [Abstract]
Revenue Recognition	3. Revenue Recognition—Effective January 1, 2018, the Company adopted ASC 606, Revenue Recognition. The Company recognizes revenue from the sale of its products, which include insecticides, herbicides, soil fumigants, and fungicides. The Company sells its products to customers, which include distributors and retailers. In addition, the Company recognizes royalty income from the sale of intellectual property. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information of sales disaggregated by category and geographic region Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 As reported Without adoption of ASC 606 As reported Without adoption of ASC 606 Net sales: Crop: Insecticides $ 36,509 $ 36,515 $ 76,692 $ 76,722 Herbicides/soil fumigants/fungicides 37,203 37,203 68,738 68,738 Other, including plant growth regulators and distribution 22,173 22,173 37,843 37,843 95,885 95,891 183,273 183,303 Non-crop, including distribution 17,219 17,219 29,507 29,507 Total net sales: $ 113,104 $ 113,110 $ 212,780 $ 212,810 Net sales: US $ 64,530 $ 64,536 $ 126,067 $ 126,097 International 48,574 48,574 86,713 86,713 Total net sales: $ 113,104 $ 113,110 $ 212,780 $ 212,810 Timing of revenue recognition: Goods transferred at a point in time $ 113,104 $ 113,110 $ 212,401 $ 212,810 Goods and services transferred over time — — 379 — Total net sales: $ 113,104 $ 113,110 $ 212,780 $ 212,810 Performance Obligations — A performance obligation is a promise in a contract or sales order to transfer a distinct good or service to the customer, and is the unit of account in ASC 606. A transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Certain of the Company’s sales orders have multiple performance obligations, as the promise to transfer individual goods or services is separately identifiable from other promises in the sales orders. For sales orders with multiple performance obligations, the Company allocates the sales order’s transaction price to each performance obligation based on its relative stand-alone selling price. The stand-alone selling prices are determined based on the prices at which the Company separately sells these products. The Company’s performance obligations are satisfied either at a point in time or over time as work progresses. As of June 30, 2019, the Company had $751 of remaining performance obligations, which is comprised of deferred revenue and services not yet delivered. The Company expects to recognize approximately all of its remaining performance obligations as revenue in fiscal 2019. Contract Balances — The timing of revenue recognition, billings and cash collections results in deferred revenue in the condensed consolidated balance sheets. The Company sometimes receives payments from its customers in advance of goods and services being provided in return for early cash incentive programs, resulting in deferred revenues. These related assets and liabilities are reported on the condensed consolidated balance sheet at the end of each reporting period. June 30, 2019 December 31, 2018 Total receivables, net $ 131,030 $ 134,029 Contract assets 3,200 3,000 Deferred revenue 751 20,043 Revenue recognized for the three and six months ended June 30, 2019, that was included in the deferred revenue at the beginning of 2019 were $3,408 and $19,349, respectively.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	4. Property, plant and equipment at June 30, 2019 and December 31, 2018 consists of the following: June 30, 2019 December 31, 2018 Land $ 2,548 $ 2,548 Buildings and improvements 17,902 17,555 Machinery and equipment 109,901 109,064 Office furniture, fixtures and equipment 6,067 5,655 Automotive equipment 1,694 1,116 Construction in progress 7,239 2,513 Total gross value 145,351 138,451 Less accumulated depreciation (91,714 ) (89,199 ) Total net value $ 53,637 $ 49,252 The Company recognized depreciation expense related to property, plant and equipment of $1,577 and $2,055 for the three months ended June 30, 2019 and 2018, respectively. During the three months ended June 30, 2019, the Company did not eliminate any assets and accumulated depreciation. During the three months ended June 30, 2018, the Company eliminated $3,219 of fully depreciated assets. The Company recognized depreciation expense related to property, plant and equipment of $3,225 and $4,146 for the six months ended June 30, 2019 and 2018, respectively. During the six months ended June 30, 2019 and 2018, the Company eliminated from assets and accumulated depreciation $710 and $3,347, respectively, of fully depreciated assets. Substantially all of the Company’s assets are pledged as collateral to its banks.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	5. As of June 30, 2019, we believe that inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The components of inventories consist of the following: June 30, 2019 December 31, 2018 Finished products $ 179,224 $ 147,297 Raw materials 14,169 12,598 $ 193,393 $ 159,895

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Segment Reporting	6. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows: For the three months ended June 30, 2019 2018 Change % Change Net sales: US crop $ 47,311 $ 51,760 $ (4,449 ) -9 % US non-crop 17,219 12,603 4,616 37 % US total 64,530 64,363 167 0 % International 48,574 42,683 5,891 14 % Net sales: $ 113,104 $ 107,046 $ 6,058 6 % Gross profit: US crop $ 18,719 $ 26,222 $ (7,503 ) -29 % US non-crop 8,558 6,352 2,206 35 % US total 27,277 32,574 (5,297 ) -16 % International 14,376 10,723 3,653 34 % Total gross profit: $ 41,653 $ 43,297 $ (1,644 ) -4 % For the six months ended June 30, 2019 2018 Change % Change Net sales: US crop $ 96,560 $ 108,785 $ (12,225 ) -11 % US non-crop 29,507 25,393 4,114 16 % US total 126,067 134,178 (8,111 ) -6 % International 86,713 76,976 9,737 13 % Net sales: $ 212,780 $ 211,154 $ 1,626 1 % Gross profit: US crop $ 42,214 $ 50,753 $ (8,539 ) -17 % US non-crop 14,872 12,432 2,440 20 % US total 57,086 63,185 (6,099 ) -10 % International 26,269 21,163 5,106 24 % Total gross profit: $ 83,355 $ 84,348 $ (993 ) -1 %

Accrued Program Costs

Accrued Program Costs	6 Months Ended
	Jun. 30, 2019
Payables And Accruals [Abstract]
Accrued Program Costs	7. Accrued Program Costs— The Company offers various discounts to customers based on the volume purchased within a defined time period, other pricing adjustments, some grower volume incentives or other key performance indicator driven payments made to distributors, retailers or growers, at the end of a growing season. The Company describes these payments as “programs.” Programs are a critical part of doing business in both the US crop and non-crop chemicals market-places. These discount programs represent variable consideration. Revenue from sales is recorded at the net sales price, which is the transaction price, and includes estimates of variable consideration. Variable consideration includes amounts expected to be paid to its customers estimated using the expected value method. Each quarter management compares individual sale transactions with programs to determine what, if any, estimated program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management, along with executive and financial management, review the accumulated program balance and, for volume driven payments, make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in agreed upon terms and conditions attached to each program. Following this assessment, management makes adjustments to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at, or close to, the end of the crop season, at which time customer performance can be more fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year. No significant changes in estimates were made during the three and six months ended June 30, 2019 and 2018, respectively.

Cash Dividend

Cash Dividend	6 Months Ended
	Jun. 30, 2019
Cash Dividends [Abstract]
Cash Dividend	8. The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid June 10, 2019 June 28, 2019 July 12, 2019 $ 0.020 $ 580 March 6, 2019 March 27, 2019 April 10, 2019 $ 0.020 $ 580 December 10, 2018 December 27, 2018 January 10, 2019 $ 0.020 $ 581

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share	9. FASB ASC 260 Earnings Per Share (“EPS”) The components of basic and diluted earnings per share were as follows: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Numerator: Net income attributable to AVD $ 3,106 $ 5,599 $ 7,012 $ 10,254 Denominator: (in thousands) Weighted average shares outstanding-basic 29,001 29,330 28,989 29,309 Dilutive effect of stock options and grants 539 860 571 804 29,540 30,190 29,560 30,113 For the three and six months ended June 30, 2019 and 2018, respectively, no stock options were excluded from the computation of diluted earnings per share.

Indebtedness

Indebtedness	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Indebtedness	10. The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2019 and December 31, 2018. The Company has no short-term debt as of June 30, 2019 and December 31, 2018. Debt is summarized in the following table: Long-term indebtedness ($000's) June 30, 2019 December 31, 2018 Revolving line of credit $ 165,200 $ 97,400 Deferred loan fees (626 ) (729 ) Net long-term debt $ 164,574 $ 96,671 As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA as defined in the Credit Agreement, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.50%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date. At June 30, 2019, according to the terms of the Credit Agreement and based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $30,557. This compares to an available borrowing capacity of $137,047, as of June 30, 2018. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA including both the trailing twelve-month period and proforma basis arising from acquisitions, which have declined, (2) net borrowings, which have increased due to recent acquisitions and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement). As of June 30, 2019, the Company was in compliance with all of its debt covenants.

Reclassification

Reclassification	6 Months Ended
	Jun. 30, 2019
Text Block [Abstract]
Reclassification	11. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the June 30, 2019 presentation.

Comprehensive income

Comprehensive income	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Comprehensive Income	12. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three and six month periods ended June 30, 2019 and 2018, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	13. Stock Based Compensation—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “ Share-Based Payment, The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three and six months ended June 30, 2019 and 2018. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Six months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) June 30, 2019 Restricted Stock $ 981 $ 1,669 $ 8,091 2.2 Unrestricted Stock 99 195 385 0.9 Performance Based Restricted Stock 430 1,131 3,863 2.2 Total $ 1,510 $ 2,995 $ 12,339 June 30, 2018 Restricted Stock $ 892 $ 1,557 $ 7,071 2.2 Unrestricted Stock 96 193 353 0.9 Performance Based Restricted Stock 481 1,028 3,336 2.2 Total $ 1,469 $ 2,778 $ 10,760 Stock Options—During the three and six months ended June 30, 2019, the Company did not grant any employees options to acquire shares of common stock. Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2018 384,064 $ 9.10 $ 9.10 Options exercised (14,677 ) 9.18 — Balance outstanding, March 31, 2019 369,387 9.10 9.10 Options exercised (4,313 ) 8.71 — Balance outstanding, June 30, 2019 365,074 $ 9.10 $ 9.10 Information relating to stock options at June 30, 2019, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 218,045 17 $ 7.5 218,045 $ 7.50 $11.32—$14.49 147,029 64 $ 11.48 147,029 $ 11.48 365,074 $ 9.10 365,074 $ 9.10 The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of June 30, 2019, were as follows: As of June 30, 2019 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 365,074 $ 9.10 36 $ 2,302 Expected to Vest 365,074 $ 9.10 36 $ 2,302 Exercisable 365,074 $ 9.10 36 $ 2,302 Common stock grants — Six Months Ended June 30, 2019 Six Months Ended June 30, 2018 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 587,210 $ 17.59 391,753 $ 15.61 Granted 297,679 17.34 254,972 19.97 Vested (105,582 ) 15.21 (8,800 ) 12.07 Forfeited (6,589 ) 17.69 (5,265 ) 16.51 Nonvested shares at March 31 st 772,718 17.77 632,660 17.41 Granted 40,522 13.34 22,308 23.66 Vested (32,771 ) 13.35 (20,313 ) 22.82 Forfeited (21,184 ) 17.77 (6,424 ) 17.25 Nonvested shares at June 30th 759,285 $ 17.72 628,231 $ 17.40 Common stock grants — During the six months ended June 30, 2019, the Company issued a total of 338,201 shares of common stock to employees and directors of which 31,771 shares vested immediately, 9,000 shares will vest between a range of 95 days to 1,115 days, 6,751 shares will vest in three equal tranches on the employee’s anniversary, and the remaining shares will cliff vest after three years of service. The shares granted in 2019 were average fair valued at $16.86 per share. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the fair value of restricted shares over the required service period. During the six months ended June 30, 2018, the Company issued a total of 277,280 shares of common stock to employees and directors of which 19,313 shares vested immediately, 19,760 shares will vest between a range of 178 days to 1,060 days, and the remaining shares will cliff vest after three years of service. The shares granted in 2018 were average fair valued at $20.27 per share. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the fair value of restricted shares over the required service period. During the three months ended June 30, 2019 and 2018, the Company recognized stock-based compensation related to restricted shares of $981 and $892, respectively. During the six months ended June 30, 2019 and 2018, the Company recognized stock-based compensation related to restricted shares of $1,669 and $1,557, respectively. As of June 30, 2019, the Company had approximately $8,091 of unamortized stock-based compensation related to unvested restricted shares. This amount will be recognized over the weighted-average period of 2.2 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance-Based Shares — Six Months Ended June 30, 2019 Six Months Ended June 30, 2018 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 287,077 $ 16.87 186,057 $ 14.93 Granted 137,557 16.47 122,446 18.79 Additional granted based on performance achievement 41,568 12.88 — — Vested (90,872 ) 14.73 (14,625 ) 11.01 Forfeited (3,543 ) 15.98 (1,765 ) 15.40 Nonvested shares at March 31 st 371,787 16.81 292,113 16.74 Granted — — 3,850 22.69 Forfeited (14,022 ) 17.11 (2,179 ) 17.67 Nonvested shares at June 30th 357,765 $ 16.80 293,784 $ 16.81 Performance-Based Shares — During the six months ended June 30, 2019, the Company issued a total of 137,557 performance-based shares to employees. The shares granted have an average fair value of $16.47. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize, as expense, the fair value of the performance based shares over the required service period from grant date. Performance-Based Shares — During the six months ended June 30, 2018, the Company issued a total of 126,296 performance-based shares to employees. The shares granted have an average fair value of $18.91. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the fair value of the performance-based shares over the required service period from grant date. As of June 30, 2019, performance-based shares related to EBIT and net sales have an average fair value of $17.34 per share. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $15.46 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period. During the three months ended June 30, 2019 and 2018, the Company recognized stock-based compensation related to performance-based shares of $430 and $481, respectively. During the six months ended June 30, 2019 and 2018, the Company recognized stock-based compensation related to performance based shares of $1,131 and $1,028, respectively. As of June 30, 2019, the Company had approximately $3,863 of unamortized stock-based compensation expense related to unvested performance-based shares. This amount will be recognized over the weighted-average period of 2.2 years. This projected expense will change if any performance-based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Incentive Stock Options—During the six months ended June 30, 2019 and 2018, the Company did not grant any employees performance incentive stock options to acquire shares of common stock. Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2018 140,411 $ 11.49 $ 11.49 Options exercised (5,735 ) 11.49 11.49 Balance outstanding, March 31, 2019 and June 30, 2019 134,676 $ 11.49 $ 11.49 Information relating to stock options at June 30, 2019 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 134,676 66 $ 11.49 134,676 $ 11.49 The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2019 are as follows: As of June 30, 2019 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 134,676 $ 11.49 66 $ 528 Expected to Vest 134,676 $ 11.49 66 $ 528 Exercisable 134,676 $ 11.49 66 $ 528

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	14. Legal Proceedings — During the reporting period, there have been no material developments in legal proceedings that were reported in the Company’s Form 10-K for the year ended December 31, 2018, except as described below. EPA FIFRA/RCRA Matter. Takings Case.

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Recently Issued Accounting Guidance	15.Recently Issued Accounting Guidance: Accounting standards adopted in 2019: In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02 and subsequent amendments, collectively known as ASC 842, Leases. ASC 842 requires recognition of operating leases as lease assets and liabilities on the balance sheet and requires the disclosure of key information about leasing arrangements. The Company elected to adopt ASC 842 by applying the modified transition method and, in addition, elected to use the effective date of January 1, 2019 as the initial date of application. We elected to apply all relevant practical expedients permitted under the transition guidance within the new lease standard with the exception of the practical expedient allowing the use of hindsight in determining the lease term and in assessing impairment. The new standard also provides practical expedients for an entity’s ongoing accounting. We elected an accounting policy to keep leases with an initial term of 12 months or less off the balance sheet and to recognize those lease payments in the condensed consolidated statements of operations on a straight-line basis over the lease term. We also elected the practical expedient to not separate lease and non-lease components for all of our leases, except for warehouse leases. The adoption of ASC 842 resulted in the recognition of operating lease ROU assets of $12,936 and operating lease liabilities of $12,936 on the effective date as of January 1, 2019. The new guidance did not have a material impact on the condensed consolidated statement of operations or statement of cash flows. The accounting for finance leases under ASC 842 remained substantially unchanged from previous accounting guidance and are not material. See Note 2 for the disclosures required by ASC 842 and accounting policy information for leases. In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (ASC 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In January 2018, the FASB released guidance on the accounting for tax on the global intangible low-taxed income (“GILTI”) provisions of the Tax Cuts and Jobs Act (the “Act”). The GILTI provisions imposed a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has considered options regarding the accounting treatment for any potential GILTI inclusions and has elected to treat such inclusions as period costs. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (ASC 350). Accounting standards not yet adopted: In June 2016, the FASB issued ASU 2016-13 " Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	16. Fair Value of Financial Instruments— The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt payable to the bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt payable to bank. As of June 30, 2019, the Company reassessed the fair value of the deferred consideration balances relating to the 2017 AgriCenter and OHP acquisitions, which resulted in a combined reduction of the deferred consideration balances in the amount of $1,345 and $2,888 for the three and six months ended June 30, 2019. During both the three and six months ended June 30, 2018, the Company recognized $1,468 as reductions in deferred consideration balances related to the acquisitions. These amounts are reflected as reductions to the general and administrative expenses within operating expenses in the condensed consolidated statements of operations. The total deferred consideration reflected in the condensed consolidated balance sheets as of June 30, 2019 and 2018 was $978 and $8,267, respectively

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income ("AOCI")	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Accumulated Other Comprehensive Income ("AOCI")	17. Accumulated Other Comprehensive Income (“AOCI”) — Total Balance, December 31, 2018 $ (4,507 ) FX translation (1,769 ) Balance, March 31, 2019 (6,276 ) FX translation 657 Balance, June 30, 2019 $ (5,619 )

Investments

Investments	6 Months Ended
	Jun. 30, 2019
Equity Method Investments And Joint Ventures [Abstract]
Investments	18. Investments — The Company utilized the equity method of accounting with respect to its investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing essential oils and other natural ingredients, until the Company acquired all of TyraTech’s remaining outstanding shares as of November 8, 2018. The Company recognized losses of $347 and $443 on its equity method investment for the three and six months ended June 30, 2018. The Company’s ownership position in TyraTech was approximately 34% prior to the November 8, 2018 acquisition. On June 27, 2017, both Amvac Netherlands BV and Huifeng Agrochemical Company, Ltd (“Huifeng”) made individual capital contributions of $950 to Huifeng Amvac Innovation Co. Ltd (“Hong Kong Joint Venture”). As of June 30, 2018, the Company’s ownership position in the Hong Kong Joint Venture was 50%. The Company utilizes the equity method of accounting with respect to this investment. On July 7, 2017, the Hong Kong Joint Venture purchased the shares of Profeng Australia, Pty Ltd.(“Profeng”), for a total consideration of $1,900. The purchase consists of Profeng Australia, Pty Ltd Trustee and Profeng Australia Unit Trust. Both Trust and Trustee were previously owned by Huifeng via its wholly owned subsidiary Shanghai Biological Focus center. For the three and six months ended June 30, 2019, the Company recognized losses of $36 and $60, respectively, as a result of the Company’s ownership position in the Hong Kong Joint Venture. For the three months and six months ended June 30, 2018, the Company recognized gains of $46 and losses of $75, respectively. In February 2016, AMVAC Netherlands BV made an investment in Biological Products for Agriculture (“Bi-PA”). Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of June 30, 2019, the Company’s ownership position in Bi-PA was 15%. The Company adopted the provisions of ASU 2016-01 on January 1, 2018 and has elected to measure its cost method investment without a readily determinable fair value at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no observable price changes in the three and six months ended June 30, 2019. There was no impairment on the investment as of June 30, 2019. The investment is not material and is recorded within other assets on the condensed consolidated balance sheets.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	19. Income Taxes — Income tax expense was $1,224 for the three months ended June 30, 2019, as compared to $1,748 for the comparable period in 2018. The effective tax rate for the quarter was 28.1%, as compared to 23.0% in the same period of the prior year. Income tax expense was $2,584 for the six months ended June 30, 2019, as compared to $3,440 for the six months ended June 30, 2018. The effective tax rate for the six months ended June 30, 2019 and 2018 was 26.8% and 24.4%, respectively. The effective tax rate is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

Share Repurchase Program

Share Repurchase Program	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Share Repurchase Program	20. Share Repurchase Program – On November 5, 2018, pursuant to a Board of Directors resolution, the Company announced its intention to repurchase an aggregate amount of shares with a total purchase price not to exceed $20,000 of its common stock, par value $0.10 per share, in the open market, depending upon market conditions over the short to mid-term. The Shares Repurchase Program expired on March 8, 2019. During January 2019, the Company purchased 158,048 shares for a total of $2,604 at an average price of $16.48 per share.

Business and Asset Acquisitions

Business and Asset Acquisitions	6 Months Ended
	Jun. 30, 2019
Business Combinations [Abstract]
Business and Asset Acquisitions	21. Business and Asset Acquisitions – On January 10, 2019, the Company completed the acquisition of all of the outstanding shares of stock of two affiliated businesses, Defensive and Agrovant, which are located in Jaboticabal in the state of Sao Paul, Brazil. At closing the Company paid cash consideration of $20,695, which was net of cash acquired of $982, deferred consideration of $2,645 including contingent consideration dependent on certain financial results for 2019, and liabilities assumed of $17,040, including liabilities of $10,098 related to income tax matters. These companies were founded in 2000 and are suppliers of crop protection products and micronutrients with focus on the fruit and vegetable market segments. The acquisition was accounted for as a business combination and the total value of $40,370 has been preliminarily allocated as follows: product registrations and product rights $9,451, trade name $1,733, customer relationships $3,114, goodwill $14,224, working capital $8,072, fixed assets $404 and indemnification assets $3,385. The operating results of the acquired businesses are included in our condensed consolidated statement of operations from the date of acquisition. The Company paid E.I. DuPont et Nemours additional cash consideration in the amount of $3,564 related to one product line acquisition made at the end of 2018.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Event	22. Subsequent event – On July 1, 2019, AMVAC completed the acquisition of certain rights and the assumption of certain liabilities relating to three product lines (etoxazole, bispyribac sodium and diflubenzuron) from Raymat Crop Science, Inc. (and certain of its affiliates). The purchase price was immaterial to the condensed consolidated financial statements. With respect to etoxazole and bispyribac sodium, AMVAC obtained registrations, trademarks (“Stifle” and “Arroz 80”) and inventories. With respect to diflubenzuron, AMVAC became the exclusive distributor of end-use products within the United States.

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Schedule of Additional Information of Operating Leases	Additional information related to operating leases are as follows: Three months ended March 31, 2019 Six months ended June 30, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 1,348 $ 2,685 ROU assets obtained in exchange for new liabilities $ 1,682 $ 2,052
Schedule of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases	The weighted-average remaining lease term and discount rate related to the operating leases as of June 30, 2019 were as follows: Weighted-average remaining lease term (in years) 3.44 Weighted-average discount rate 3.71 %
Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases	Future minimum lease payments under non-cancellable operating leases as of June 30, 2019 were as follows: June 30, 2019 Remainder of 2019 $ 2,611 2020 4,792 2021 2,834 2022 1,299 2023 688 Thereafter 1,183 Total lease payments $ 13,407 Less: imputed interest 914 Total $ 12,493 Amounts recognized in the condensed consolidated balance sheet: Operating lease liabilities, current $ 4,749 Operating lease liabilities, long term $ 7,744

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2019
Revenue From Contract With Customer [Abstract]
Summary of Selective Enterprise Information of Sales Disaggregated By Category and Geographic Region	Selective enterprise information of sales disaggregated by category and geographic region Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 As reported Without adoption of ASC 606 As reported Without adoption of ASC 606 Net sales: Crop: Insecticides $ 36,509 $ 36,515 $ 76,692 $ 76,722 Herbicides/soil fumigants/fungicides 37,203 37,203 68,738 68,738 Other, including plant growth regulators and distribution 22,173 22,173 37,843 37,843 95,885 95,891 183,273 183,303 Non-crop, including distribution 17,219 17,219 29,507 29,507 Total net sales: $ 113,104 $ 113,110 $ 212,780 $ 212,810 Net sales: US $ 64,530 $ 64,536 $ 126,067 $ 126,097 International 48,574 48,574 86,713 86,713 Total net sales: $ 113,104 $ 113,110 $ 212,780 $ 212,810 Timing of revenue recognition: Goods transferred at a point in time $ 113,104 $ 113,110 $ 212,401 $ 212,810 Goods and services transferred over time — — 379 — Total net sales: $ 113,104 $ 113,110 $ 212,780 $ 212,810
Summary of Contract Balances	June 30, 2019 December 31, 2018 Total receivables, net $ 131,030 $ 134,029 Contract assets 3,200 3,000 Deferred revenue 751 20,043

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Summary of Property, Plant and Equipment	Property, plant and equipment at June 30, 2019 and December 31, 2018 consists of the following: June 30, 2019 December 31, 2018 Land $ 2,548 $ 2,548 Buildings and improvements 17,902 17,555 Machinery and equipment 109,901 109,064 Office furniture, fixtures and equipment 6,067 5,655 Automotive equipment 1,694 1,116 Construction in progress 7,239 2,513 Total gross value 145,351 138,451 Less accumulated depreciation (91,714 ) (89,199 ) Total net value $ 53,637 $ 49,252

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Components of Inventories	The components of inventories consist of the following: June 30, 2019 December 31, 2018 Finished products $ 179,224 $ 147,297 Raw materials 14,169 12,598 $ 193,393 $ 159,895

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Summary of Business Sales Segmentation	Selective enterprise information is as follows: For the three months ended June 30, 2019 2018 Change % Change Net sales: US crop $ 47,311 $ 51,760 $ (4,449 ) -9 % US non-crop 17,219 12,603 4,616 37 % US total 64,530 64,363 167 0 % International 48,574 42,683 5,891 14 % Net sales: $ 113,104 $ 107,046 $ 6,058 6 % Gross profit: US crop $ 18,719 $ 26,222 $ (7,503 ) -29 % US non-crop 8,558 6,352 2,206 35 % US total 27,277 32,574 (5,297 ) -16 % International 14,376 10,723 3,653 34 % Total gross profit: $ 41,653 $ 43,297 $ (1,644 ) -4 % For the six months ended June 30, 2019 2018 Change % Change Net sales: US crop $ 96,560 $ 108,785 $ (12,225 ) -11 % US non-crop 29,507 25,393 4,114 16 % US total 126,067 134,178 (8,111 ) -6 % International 86,713 76,976 9,737 13 % Net sales: $ 212,780 $ 211,154 $ 1,626 1 % Gross profit: US crop $ 42,214 $ 50,753 $ (8,539 ) -17 % US non-crop 14,872 12,432 2,440 20 % US total 57,086 63,185 (6,099 ) -10 % International 26,269 21,163 5,106 24 % Total gross profit: $ 83,355 $ 84,348 $ (993 ) -1 %

Cash Dividend (Tables)

Cash Dividend (Tables)	6 Months Ended
	Jun. 30, 2019
Cash Dividends [Abstract]
Cash Dividend	The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid June 10, 2019 June 28, 2019 July 12, 2019 $ 0.020 $ 580 March 6, 2019 March 27, 2019 April 10, 2019 $ 0.020 $ 580 December 10, 2018 December 27, 2018 January 10, 2019 $ 0.020 $ 581

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Numerator: Net income attributable to AVD $ 3,106 $ 5,599 $ 7,012 $ 10,254 Denominator: (in thousands) Weighted average shares outstanding-basic 29,001 29,330 28,989 29,309 Dilutive effect of stock options and grants 539 860 571 804 29,540 30,190 29,560 30,113

Indebtedness (Tables)

Indebtedness (Tables)	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Summary of Debt	The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2019 and December 31, 2018. The Company has no short-term debt as of June 30, 2019 and December 31, 2018. Debt is summarized in the following table: Long-term indebtedness ($000's) June 30, 2019 December 31, 2018 Revolving line of credit $ 165,200 $ 97,400 Deferred loan fees (626 ) (729 ) Net long-term debt $ 164,574 $ 96,671

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period	The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three and six months ended June 30, 2019 and 2018. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Six months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) June 30, 2019 Restricted Stock $ 981 $ 1,669 $ 8,091 2.2 Unrestricted Stock 99 195 385 0.9 Performance Based Restricted Stock 430 1,131 3,863 2.2 Total $ 1,510 $ 2,995 $ 12,339 June 30, 2018 Restricted Stock $ 892 $ 1,557 $ 7,071 2.2 Unrestricted Stock 96 193 353 0.9 Performance Based Restricted Stock 481 1,028 3,336 2.2 Total $ 1,469 $ 2,778 $ 10,760
Summary of Option Activity	Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2018 384,064 $ 9.10 $ 9.10 Options exercised (14,677 ) 9.18 — Balance outstanding, March 31, 2019 369,387 9.10 9.10 Options exercised (4,313 ) 8.71 — Balance outstanding, June 30, 2019 365,074 $ 9.10 $ 9.10
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at June 30, 2019, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 218,045 17 $ 7.5 218,045 $ 7.50 $11.32—$14.49 147,029 64 $ 11.48 147,029 $ 11.48 365,074 $ 9.10 365,074 $ 9.10
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of June 30, 2019, were as follows: As of June 30, 2019 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 365,074 $ 9.10 36 $ 2,302 Expected to Vest 365,074 $ 9.10 36 $ 2,302 Exercisable 365,074 $ 9.10 36 $ 2,302
Performance Based Stock Options
Summary of Option Activity	Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2018 140,411 $ 11.49 $ 11.49 Options exercised (5,735 ) 11.49 11.49 Balance outstanding, March 31, 2019 and June 30, 2019 134,676 $ 11.49 $ 11.49
Performance Incentive Stock Option Plan
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at June 30, 2019 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 134,676 66 $ 11.49 134,676 $ 11.49
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2019 are as follows: As of June 30, 2019 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 134,676 $ 11.49 66 $ 528 Expected to Vest 134,676 $ 11.49 66 $ 528 Exercisable 134,676 $ 11.49 66 $ 528
Common Stock Grants
Summary of Non-Vested Shares	Common stock grants — Six Months Ended June 30, 2019 Six Months Ended June 30, 2018 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 587,210 $ 17.59 391,753 $ 15.61 Granted 297,679 17.34 254,972 19.97 Vested (105,582 ) 15.21 (8,800 ) 12.07 Forfeited (6,589 ) 17.69 (5,265 ) 16.51 Nonvested shares at March 31 st 772,718 17.77 632,660 17.41 Granted 40,522 13.34 22,308 23.66 Vested (32,771 ) 13.35 (20,313 ) 22.82 Forfeited (21,184 ) 17.77 (6,424 ) 17.25 Nonvested shares at June 30th 759,285 $ 17.72 628,231 $ 17.40
Performance Based Restricted Shares
Summary of Non-Vested Shares	Performance-Based Shares — Six Months Ended June 30, 2019 Six Months Ended June 30, 2018 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 287,077 $ 16.87 186,057 $ 14.93 Granted 137,557 16.47 122,446 18.79 Additional granted based on performance achievement 41,568 12.88 — — Vested (90,872 ) 14.73 (14,625 ) 11.01 Forfeited (3,543 ) 15.98 (1,765 ) 15.40 Nonvested shares at March 31 st 371,787 16.81 292,113 16.74 Granted — — 3,850 22.69 Forfeited (14,022 ) 17.11 (2,179 ) 17.67 Nonvested shares at June 30th 357,765 $ 16.80 293,784 $ 16.81

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income ("AOCI") (Tables)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: Total Balance, December 31, 2018 $ (4,507 ) FX translation (1,769 ) Balance, March 31, 2019 (6,276 ) FX translation 657 Balance, June 30, 2019 $ (5,619 )

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)
Leases [Line Items]
Operating lease expenses	$ 1,400	$ 2,758
Minimum
Leases [Line Items]
Operating lease term	1 year	1 year
Maximum
Leases [Line Items]
Operating lease term	15 years	15 years

Leases - Schedule of Additional

Leases - Schedule of Additional Information of Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2019	Jun. 30, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 1,348	$ 2,685
ROU assets obtained in exchange for new liabilities	$ 1,682	$ 2,052

Leases - Schedule of Weighted-A

Leases - Schedule of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Detail)	Jun. 30, 2019
Leases [Abstract]
Weighted-average remaining lease term (in years)	3 years 5 months 8 days
Weighted-average discount rate	3.71%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
Leases [Abstract]
Remainder of 2019	$ 2,611
2020	4,792
2021	2,834
2022	1,299
2023	688
Thereafter	1,183
Total lease payments	13,407
Less: imputed interest	914
Total	12,493	$ 12,936
Amounts recognized in the condensed consolidated balance sheet:
Operating lease liabilities, current	4,749
Operating lease liabilities, long term	$ 7,744

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)Segment
Revenue From Contract With Customer [Abstract]
Number of reportable segments | Segment		1
Remaining performance obligations	$ 751	$ 751
Revenue recognized	$ 3,408	$ 19,349

Revenue Recognition - Summary o

Revenue Recognition - Summary of Selective Enterprise Information of Sales Disaggregated By Category and Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation Of Revenue [Line Items]
Net sales	$ 113,104	$ 107,046	$ 212,780	$ 211,154
Insecticides
Disaggregation Of Revenue [Line Items]
Net sales	36,509		76,692
Herbicides/Soil Fumigants/Fungicides
Disaggregation Of Revenue [Line Items]
Net sales	37,203		68,738
Other, Including Plant Growth Regulators and Distribution
Disaggregation Of Revenue [Line Items]
Net sales	22,173		37,843
Crop
Disaggregation Of Revenue [Line Items]
Net sales	95,885		183,273
Non-crop, Including Distribution
Disaggregation Of Revenue [Line Items]
Net sales	17,219		29,507
US
Disaggregation Of Revenue [Line Items]
Net sales	64,530	64,363	126,067	134,178
US | Crop
Disaggregation Of Revenue [Line Items]
Net sales	47,311	51,760	96,560	108,785
International
Disaggregation Of Revenue [Line Items]
Net sales	48,574	$ 42,683	86,713	$ 76,976
Goods Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Net sales	113,104		212,401
Goods and Services Transferred Over Time
Disaggregation Of Revenue [Line Items]
Net sales			379
Balances without adoption of ASC 606
Disaggregation Of Revenue [Line Items]
Net sales	113,110		212,810
Balances without adoption of ASC 606 | Insecticides
Disaggregation Of Revenue [Line Items]
Net sales	36,515		76,722
Balances without adoption of ASC 606 | Herbicides/Soil Fumigants/Fungicides
Disaggregation Of Revenue [Line Items]
Net sales	37,203		68,738
Balances without adoption of ASC 606 | Other, Including Plant Growth Regulators and Distribution
Disaggregation Of Revenue [Line Items]
Net sales	22,173		37,843
Balances without adoption of ASC 606 | Crop
Disaggregation Of Revenue [Line Items]
Net sales	95,891		183,303
Balances without adoption of ASC 606 | Non-crop, Including Distribution
Disaggregation Of Revenue [Line Items]
Net sales	17,219		29,507
Balances without adoption of ASC 606 | US
Disaggregation Of Revenue [Line Items]
Net sales	64,536		126,097
Balances without adoption of ASC 606 | International
Disaggregation Of Revenue [Line Items]
Net sales	48,574		86,713
Balances without adoption of ASC 606 | Goods Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Net sales	$ 113,110		$ 212,810

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Contract Balances (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Revenue From Contract With Customer [Abstract]
Total receivables, net	$ 131,030	$ 134,029
Contract assets	3,200	3,000
Deferred revenue	$ 751	$ 20,043

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total gross value	$ 145,351	$ 138,451
Less accumulated depreciation	(91,714)	(89,199)
Total net value	53,637	49,252
Land
Property, Plant and Equipment [Line Items]
Total gross value	2,548	2,548
Buildings and improvements
Property, Plant and Equipment [Line Items]
Total gross value	17,902	17,555
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total gross value	109,901	109,064
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total gross value	6,067	5,655
Automotive equipment
Property, Plant and Equipment [Line Items]
Total gross value	1,694	1,116
Construction in progress
Property, Plant and Equipment [Line Items]
Total gross value	$ 7,239	$ 2,513

Property, Plant And Equipment -

Property, Plant And Equipment - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Depreciation expense related to property, plant and equipment	$ 1,577,000	$ 2,055,000	$ 3,225,000	$ 4,146,000
Elimination of Assets and Accumulated depreciation	$ 0	$ 3,219,000	$ 710,000	$ 3,347,000

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Finished products	$ 179,224	$ 147,297
Raw materials	14,169	12,598
Total Inventories	$ 193,393	$ 159,895

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2019Segment
Segment Reporting [Abstract]
Number of reportable business segments	1

Summary of Business Sales by Pr

Summary of Business Sales by Product and Geographic Location (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net sales
Net sales	$ 113,104	$ 107,046	$ 212,780	$ 211,154
Change in net sales	$ 6,058		$ 1,626
Percentage change in net sales	6.00%		1.00%
Gross profit:
Total gross profit	$ 41,653	43,297	$ 83,355	84,348
Change in gross profit	$ (1,644)		$ (993)
Percentage change in gross profit	(4.00%)		(1.00%)
Crop
Net sales
Net sales	$ 95,885		$ 183,273
US
Net sales
Net sales	64,530	64,363	126,067	134,178
Change in net sales	$ 167		$ (8,111)
Percentage change in net sales	0.00%		(6.00%)
Gross profit:
Total gross profit	$ 27,277	32,574	$ 57,086	63,185
Change in gross profit	$ (5,297)		$ (6,099)
Percentage change in gross profit	(16.00%)		(10.00%)
US | Crop
Net sales
Net sales	$ 47,311	51,760	$ 96,560	108,785
Change in net sales	$ (4,449)		$ (12,225)
Percentage change in net sales	(9.00%)		(11.00%)
Gross profit:
Total gross profit	$ 18,719	26,222	$ 42,214	50,753
Change in gross profit	$ (7,503)		$ (8,539)
Percentage change in gross profit	(29.00%)		(17.00%)
US | Non Crop
Net sales
Net sales	$ 17,219	12,603	$ 29,507	25,393
Change in net sales	$ 4,616		$ 4,114
Percentage change in net sales	37.00%		16.00%
Gross profit:
Total gross profit	$ 8,558	6,352	$ 14,872	12,432
Change in gross profit	$ 2,206		$ 2,440
Percentage change in gross profit	35.00%		20.00%
International
Net sales
Net sales	$ 48,574	42,683	$ 86,713	76,976
Change in net sales	$ 5,891		$ 9,737
Percentage change in net sales	14.00%		13.00%
Gross profit:
Total gross profit	$ 14,376	$ 10,723	$ 26,269	$ 21,163
Change in gross profit	$ 3,653		$ 5,106
Percentage change in gross profit	34.00%		24.00%

Cash Dividend (Detail)

Cash Dividend (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Supplemental Cash Flow Elements [Abstract]
Cash dividend declaration date	Jun. 10, 2019	Mar. 6, 2019	Dec. 10, 2018
Cash dividend record date	Jun. 28, 2019	Mar. 27, 2019	Dec. 27, 2018
Cash dividend distributed date	Jul. 12, 2019	Apr. 10, 2019	Jan. 10, 2019
Cash dividend per share	$ 0.020	$ 0.020	$ 0.020
Cash dividend paid	$ 580	$ 580	$ 581

Components of Basic and Diluted

Components of Basic and Diluted Earnings Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Numerator:
Net income attributable to AVD	$ 3,106	$ 5,599	$ 7,012	$ 10,254
Denominator:
Weighted average shares outstanding-basic	29,001	29,330	28,989	29,309
Dilutive effect of stock options and grants	539	860	571	804
Weighted average shares outstanding-diluted	29,540	30,190	29,560	30,113

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Stock options excluded from computation of diluted earning per share	0	0	0	0

Indebtedness - Additional Infor

Indebtedness - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2017	Dec. 31, 2018	Jun. 30, 2018
Debt Instrument [Line Items]
Short term debt	$ 0		$ 0
Senior Secured Revolving Line of Credit
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement				$ 137,047,000
Senior secured credit facility, maturity date		Jun. 30, 2022
Credit agreement, covenant description	The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1.
Credit agreement, variable rate description	Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.50%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”).
Federal Funds Rate | Senior Secured Revolving Line of Credit
Debt Instrument [Line Items]
Credit agreement, variable rate basis		0.50%
One-Month LIBOR Rate | Senior Secured Revolving Line of Credit
Debt Instrument [Line Items]
Credit agreement, variable rate basis		1.00%
Eurocurrency Rate | Senior Secured Revolving Line of Credit
Debt Instrument [Line Items]
Credit agreement, interest payment period, description	last day of each interest period (either one, two, three or six months, as selected by the borrower)
Alternate Base Rate | Senior Secured Revolving Line of Credit
Debt Instrument [Line Items]
Credit agreement, interest payment period, description	last business day of each month
Maximum | Senior Secured Revolving Line of Credit
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement		$ 250,000,000
Consolidated funded debt ratio		325.00%
Capacity to increase borrowings under credit agreement	$ 30,557,000
Maximum | Term Loan
Debt Instrument [Line Items]
Accordion feature		$ 100,000,000
Minimum
Debt Instrument [Line Items]
Consolidated fixed charge covenant ratio		125.00%

Summary of Debt (Detail)

Summary of Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Revolving line of credit	$ 165,200	$ 97,400
Deferred loan fees	(626)	(729)
Net long-term debt	$ 164,574	$ 96,671

Unamortized Stock-Based Compens

Unamortized Stock-Based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 1,510	$ 1,469	$ 2,995	$ 2,778
Unamortized Stock-Based Compensation	12,339	10,760	$ 12,339	10,760
Remaining Weighted Average Period (years)			2 years 2 months 12 days
Unamortized Stock-Based Compensation	3,863		$ 3,863
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	981	892	$ 1,669	$ 1,557
Remaining Weighted Average Period (years)			2 years 2 months 12 days	2 years 2 months 12 days
Unamortized Stock-Based Compensation	8,091	7,071	$ 8,091	$ 7,071
Unrestricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	99	96	$ 195	$ 193
Remaining Weighted Average Period (years)			10 months 24 days	10 months 24 days
Unamortized Stock-Based Compensation	385	353	$ 385	$ 353
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	430	481	$ 1,131	$ 1,028
Remaining Weighted Average Period (years)			2 years 2 months 12 days	2 years 2 months 12 days
Unamortized Stock-Based Compensation	$ 3,863	$ 3,336	$ 3,863	$ 3,336

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,510		$ 1,469		$ 2,995	$ 2,778
Unamortized Stock-Based Compensation	$ 3,863				$ 3,863
Remaining Weighted Average Period (years)					2 years 2 months 12 days
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted					0	0
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employees options granted	0				0
Common Stock Grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested	32,771	105,582	20,313	8,800
Weighted Average Grant-Date Fair Value, Granted	$ 13.34	$ 17.34	$ 23.66	$ 19.97
Stock-based compensation	$ 981		$ 892		$ 1,669	$ 1,557
Unamortized Stock-Based Compensation	$ 8,091		$ 7,071		$ 8,091	$ 7,071
Remaining Weighted Average Period (years)					2 years 2 months 12 days	2 years 2 months 12 days
Number of Shares, Granted	40,522	297,679	22,308	254,972
Common Stock Grants | Employee and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested						19,313
Number of shares expected to vest			19,760			19,760
Common Stock Grants | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted					$ 16.86	$ 20.27
Common Stock Grants | Common Stock | Employee and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued by equity investee					338,201	277,280
Common Stock Grants | Vested immediately | Employee and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested					31,771
Common Stock Grants | Vesting Between 95 Days to 1,115 Days | Employee and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest	9,000				9,000
Common Stock Grants | After One Year | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting					95 days	178 days
Common Stock Grants | After One Year | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting					1115 days	1060 days
Common Stock Grants | Three Equal Tranches | Employee and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest	6,751				6,751
Common Stock Grants | After Three Years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting					3 years	3 years
Unvested Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized Stock-Based Compensation	$ 8,091				$ 8,091
Remaining Weighted Average Period (years)						2 years 2 months 12 days
Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested		90,872		14,625
Weighted Average Grant-Date Fair Value, Granted		$ 16.47	$ 22.69	$ 18.79	$ 16.47	$ 18.91
Stock-based compensation	430		$ 481		$ 1,131	$ 1,028
Unamortized Stock-Based Compensation	$ 3,863		$ 3,336		$ 3,863	$ 3,336
Remaining Weighted Average Period (years)					2 years 2 months 12 days	2 years 2 months 12 days
Number of Shares, Granted		137,557	3,850	122,446	137,557	126,296
Targeted performance percentage	200.00%		200.00%		200.00%	200.00%
Performance Based Restricted Shares | Vested on March 28, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cliff vesting date					Mar. 28, 2022
Performance Based Restricted Shares | Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2019 through December 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance					80.00%
Earnings before income taxes goal weight, percentage					50.00%
Net sales goal weight, percentage					30.00%
Performance Based Restricted Shares | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2019 through December 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income taxes goal weight, percentage					20.00%
Performance Based Restricted Shares | Vested on March 9, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cliff vesting date						Mar. 9, 2021
Performance Based Restricted Shares | Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2018 and ending December 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance						80.00%
Earnings before income taxes goal weight, percentage						50.00%
Net sales goal weight, percentage						30.00%
Performance Based Restricted Shares | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2018 and ending December 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income taxes goal weight, percentage						20.00%
Performance Based Restricted Shares | Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing January 1, 2019 and Ending December 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted					$ 17.34
Performance Based Restricted Shares | Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing January 1, 2019 and Ending December 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted					$ 15.46

Summary of Option Activity (Det

Summary of Option Activity (Detail) - Incentive Stock Options - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	369,387	384,064	384,064
Incentive Stock Option Plans, Option exercised	(4,313)	(14,677)
Incentive Stock Option Plans, Ending balance	365,074	369,387	365,074
Weighted Average Price Per Share, Beginning balance	$ 9.10	$ 9.10	$ 9.10
Weighted Average Price Per Share, Option exercised	8.71	9.18
Weighted Average Price Per Share, Ending balance	9.10	9.10	9.10
Exercisable Weighted Average Price Per Share, Beginning balance	9.10	9.10	9.10
Exercisable Weighted Average Price Per Share, Ending balance	$ 9.10	$ 9.10	$ 9.10

Summary of Stock Options Summar

Summary of Stock Options Summarized by Exercise Price (Detail) - Incentive Stock Options - $ / shares	6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	365,074
Outstanding Weighted Average, Exercise Price	$ 9.10	$ 9.10	$ 9.10
Exercisable Weighted Average, Shares	365,074
Exercisable Weighted Average, Exercise Price	$ 9.10	$ 9.10	$ 9.10
Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 7.50
Outstanding Weighted Average, Shares	218,045
Outstanding Weighted Average, Remaining Life (Months)	17 months
Outstanding Weighted Average, Exercise Price	$ 7.5
Exercisable Weighted Average, Shares	218,045
Exercisable Weighted Average, Exercise Price	$ 7.50
Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	11.32
Exercise Price Per Share, Upper Range	$ 14.49
Outstanding Weighted Average, Shares	147,029
Outstanding Weighted Average, Remaining Life (Months)	64 months
Outstanding Weighted Average, Exercise Price	$ 11.48
Exercisable Weighted Average, Shares	147,029
Exercisable Weighted Average, Exercise Price	$ 11.48

Weighted Average Exercise Price

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) - Incentive Stock Option Plan $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding | shares	365,074
Number of Shares, Expected to Vest | shares	365,074
Number of Shares, Exercisable | shares	365,074
Weighted Average Exercise Price, Outstanding | $ / shares	$ 9.10
Weighted Average Exercise Price, Expected to Vest | $ / shares	9.10
Weighted Average Exercisable, Exercise Price | $ / shares	$ 9.10
Weighted Average Remaining Life, Outstanding	36 months
Weighted Average Remaining Contractual Life, Expected to Vest	36 months
Weighted Average Remaining Contractual Life, Exercisable	36 months
Intrinsic Value, Outstanding | $	$ 2,302
Intrinsic Value, Expected to Vest | $	2,302
Intrinsic Value, Exercisable | $	$ 2,302

Summary of Non-Vested Shares (D

Summary of Non-Vested Shares (Detail) - Common Stock Grants - $ / shares	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	772,718	587,210	632,660	391,753	587,210	391,753
Number of Shares, Granted	40,522	297,679	22,308	254,972
Number of Shares, Vested	(32,771)	(105,582)	(20,313)	(8,800)
Number of Shares, Forfeited	(21,184)	(6,589)	(6,424)	(5,265)
Number of Shares, Ending Balance	759,285	772,718	628,231	632,660	759,285	628,231
Weighted Average Grant-Date Fair Value, Beginning balance	$ 17.77	$ 17.59	$ 17.41	$ 15.61	$ 17.59	$ 15.61
Weighted Average Grant-Date Fair Value, Granted	13.34	17.34	23.66	19.97
Weighted Average Grant-Date Fair Value, Vested	13.35	15.21	22.82	12.07
Weighted Average Grant-Date Fair Value, Forfeited	17.77	17.69	17.25	16.51
Weighted Average Grant-Date Fair Value, Ending balance	$ 17.72	$ 17.77	$ 17.40	$ 17.41	$ 17.72	$ 17.40

Status Summary of Non-Vested Sh

Status Summary of Non-Vested Shares (Detail) - Performance Based Restricted Shares - $ / shares	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	371,787	287,077	292,113	186,057	287,077	186,057
Number of Shares, Granted		137,557	3,850	122,446	137,557	126,296
Number of Share, Additional granted based on performance		41,568
Number of Shares, Vested		(90,872)		(14,625)
Number of Shares, Forfeited	(14,022)	(3,543)	(2,179)	(1,765)
Number of Shares, Ending Balance	357,765	371,787	293,784	292,113	357,765	293,784
Weighted Average Grant-Date Fair Value, Beginning balance	$ 16.81	$ 16.87	$ 16.74	$ 14.93	$ 16.87	$ 14.93
Weighted Average Grant-Date Fair Value, Granted		16.47	22.69	18.79	16.47	18.91
Weighted Average Grant-Date Fair Value, Additional vesting based on performance		12.88
Weighted Average Grant-Date Fair Value, Vested		14.73		11.01
Weighted Average Grant-Date Fair Value, Forfeited	17.11	15.98	17.67	15.40
Weighted Average Grant-Date Fair Value, Ending balance	$ 16.80	$ 16.81	$ 16.81	$ 16.74	$ 16.80	$ 16.81

Summary of Performance option a

Summary of Performance option activity (Detail) - Performance Based Stock Options - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	134,676	140,411	140,411
Incentive Stock Options Plans, Options exercised		(5,735)	(5,735)
Incentive Stock Option Plans, Ending balance	134,676	134,676	134,676
Weighted Average Price Per Share, Beginning balance	$ 11.49	$ 11.49	$ 11.49
Weighted Average Price Per Share, Options exercised		11.49	11.49
Weighted Average Price Per Share, Ending balance	11.49	11.49	11.49
Exercisable Weighted Average Price Per Share, Beginning balance	11.49	11.49	11.49
Exercisable Weighted Average Price Per Share, Options exercised	11.49	11.49	11.49
Exercisable Weighted Average Price Per Share, Ending balance	$ 11.49	$ 11.49	$ 11.49

Performance Options Summarized

Performance Options Summarized by Exercise Price (Detail) - Performance Incentive Stock Option Plan	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares | shares	134,676
Outstanding Weighted Average, Remaining Life (Months)	66 months
Outstanding Weighted Average, Exercise Price | $ / shares	$ 11.49
Exercisable Weighted Average, Shares | shares	134,676
Exercisable Weighted Average, Exercise Price | $ / shares	$ 11.49

Performance Option Weighted Ave

Performance Option Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) - Performance Incentive Stock Option Plan $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding | shares	134,676
Number of Shares, Expected to Vest | shares	134,676
Number of Shares, Exercisable | shares	134,676
Weighted Average Exercise Price, Outstanding | $ / shares	$ 11.49
Weighted Average Exercise Price, Expected to Vest | $ / shares	11.49
Weighted Average Exercisable, Exercise Price | $ / shares	$ 11.49
Weighted Average Remaining Life, Outstanding	66 months
Weighted Average Remaining Contractual Life, Expected to Vest	66 months
Weighted Average Remaining Contractual Life, Exercisable	66 months
Intrinsic Value, Outstanding | $	$ 528
Intrinsic Value, Expected to Vest | $	528
Intrinsic Value, Exercisable | $	$ 528

Recently Issued Accounting Gu_2

Recently Issued Accounting Guidance - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Operating lease, ROU assets	$ 12,420	$ 12,936
Operating lease, liability	$ 12,493	$ 12,936

Fair Value of Financial Instr_2

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Reduction in deferred consideration balances	$ 1,345	$ 1,468	$ 2,888	$ 1,468
Deferred consideration	$ 978		$ 978		$ 8,267

Beginning Balance, Annual Activ

Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 329,118	$ 329,230	$ 314,158	$ 305,314	$ 329,230	$ 305,314
FX translation	657	(1,769)	(898)	672	(1,112)	(226)
Balance	333,848	329,118	$ 320,231	$ 314,158	333,848	$ 320,231
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(6,276)	(4,507)			(4,507)
FX translation	657	(1,769)
Balance	$ (5,619)	$ (6,276)			$ (5,619)

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 07, 2017	Jun. 27, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Equity Method Investments [Line Items]
Gains (losses) from equity method investment					$ (60)	$ (518)
Investment		$ 950
Bi-PA
Equity Method Investments [Line Items]
Equity investment ownership position			15.00%		15.00%
Impairment on the investment			$ 0		$ 0
Profeng Australia, Pty Ltd
Equity Method Investments [Line Items]
Joint venture, consideration	$ 1,900
TyraTech Inc.
Equity Method Investments [Line Items]
Equity investment ownership position			34.00%		34.00%
Gains (losses) from equity method investment				$ (347)		$ (443)
Hong Kong JV
Equity Method Investments [Line Items]
Equity investment ownership position				50.00%		50.00%
Gains (losses) from equity method investment			$ (36)	$ 46	$ (60)	$ (75)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income tax expense	$ 1,224	$ 1,748	$ 2,584	$ 3,440
Effective tax rate	28.10%	23.00%	26.80%	24.40%

Share Repurchase Program - Addi

Share Repurchase Program - Additional Information (Detail) - USD ($)	Nov. 05, 2018	Jan. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Equity Class Of Treasury Stock [Line Items]
Common stock, par value	$ 0.10		$ 0.10	$ 0.10
Amount paid for common shares purchase		$ 2,604,000	$ 2,604,000
Common Stock
Equity Class Of Treasury Stock [Line Items]
Shares repurchase program, expiration date	Mar. 8, 2019
Number of shares purchased		158,048
Average price paid per share		$ 16.48
Common Stock | Maximum
Equity Class Of Treasury Stock [Line Items]
Number of shares intended to repurchase under repurchase program	$ 20,000

Business and Asset Acquisitio_2

Business and Asset Acquisitions - Additional Information (Detail) $ in Thousands	Jan. 10, 2019USD ($)Business	Dec. 31, 2018USD ($)Productline	Jun. 30, 2019USD ($)
Business Acquisition [Line Items]
Goodwill		$ 25,790	$ 39,436
Defensive and Agrovant
Business Acquisition [Line Items]
Number of businesses acquired | Business	2
Business combination, cash consideration	$ 20,695
Business combination, cash acquired	982
Business combination, deferred consideration paid	2,645
Business combination, liabilities assumed	17,040
Business combination, liabilities assumed, tax	10,098
Business combination, total consideration	40,370
Goodwill	14,224
Business combination, preliminary allocation of purchase price, working capital	8,072
Business combination, preliminary allocation purchase price, fixed assets	404
Business combination, preliminary allocation purchase price, indemnification assets	3,385
Defensive and Agrovant | Product Registrations and Product Rights
Business Acquisition [Line Items]
Business combination, preliminary allocation purchase price of intangible assets	9,451
Defensive and Agrovant | Trade Name
Business Acquisition [Line Items]
Business combination, preliminary allocation purchase price of intangible assets	1,733
Defensive and Agrovant | Customer Relationships
Business Acquisition [Line Items]
Business combination, preliminary allocation purchase price of intangible assets	$ 3,114
E.I DuPont et Nemour | Product Lines Acquisition
Business Acquisition [Line Items]
Business combination, cash consideration		$ 3,564
Business combination, number of product lines acquired | Productline		1

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail)	Jul. 01, 2019Productline
Subsequent Events [Abstract]
Number of product lines	3